Published on 7 May 2024 on Zacks via Yahoo Finance
ANI Pharmaceuticals ANIP is slated to report first-quarter 2024 results on May 10, before the opening bell. Investors are advised to focus on the sales performance of the company’s core business segments — rare disease and generic business.
The Zacks Consensus Estimate for the company’s earnings per share is currently pegged at 98 cents. The Zacks Consensus Estimate for total revenues is pinned at $125 million.